Drug-coated balloon angioplasty: An intriguing alternative for the treatment of coronary chronic total occlusions

Cortese, Bernardo; Buccheri, Dario; Piraino, Davide; Silva-Orrego, Pedro; Seregni, Romano

doi:10.1016/j.ijcard.2015.03.223

Cited by 11 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the incidence of re-infarct at six months was homogeneous in the two groups, at 7.5% each. Related results were seen in a trial that showed a 30-day mortality of 2.4% in the DCB subgroup [18].…”

Section: Discussionsupporting

confidence: 54%

Adverse Events in Primary Percutaneous Coronary Angioplasty With Drug-Eluting Stents Compared With Drug-Coated Balloons: A Retrospective Outlook

Khan

Malik

Mohsin

et al. 2020

Cureus

View full text Add to dashboard Cite

To compare drug-eluting stents (DES) with drug-coated balloons (DCBs) in terms of major adverse cardiovascular and cerebrovascular events (MACCE) in patients who have undergone primary percutaneous coronary intervention (PPCI). MethodologyOut of 210 angioplasties in six months, 80 patients were included; 40 in DES and 40 in DCB, respectively. All had a successful PPCI. It was defined as the achievement of thrombolysis in myocardial infarction (TIMI) grade II/III with <20% residual stenosis for the DES and TIMI grade II/III with <30% residual stenosis for the DCB. Any subsequent MACCE during the ensuing six months were assessed from emergency/outpatient records during their subsequent hospital visits, hospital registry, and telephonic interviews. ResultsThe mean age in the DES group was 54.83 + 8.72 years while it was 56.8 + 8.9 years in the DCB group. The left anterior descending artery (LAD) was the culprit artery in the majority of the cases in both groups. The mean diameter of DES and DCB was 3.17 + 0.38 mm and 2.75 + 0.53 mm, respectively. Overall, 15 adverse events were seen in the DES group and 16 in the DCB group. The difference was insignificant (P-value = ≥ 0.999). There were nine hospitalizations due to chest pain in the DES group and eight in the DCB group. Total vessel revascularization (TVR) was seen in two patients in the DES group and three patients in the DCB group. None of the patients suffered a stroke. All variables of MACCE were non-significant (P-value = ≥ 0.999). ConclusionDCB appears to be non-inferior to DES in PPCI at a median follow-up of six months.

show abstract

Section: Discussionsupporting

confidence: 54%

Adverse Events in Primary Percutaneous Coronary Angioplasty With Drug-Eluting Stents Compared With Drug-Coated Balloons: A Retrospective Outlook

Khan

Malik

Mohsin

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…There is much evidence that drug-coated balloon (DCB) treatment results in lower rates of restenosis and thrombosis and better long-term outcomes when used for PCI of in-stent restenosis (ISR) compared to plain old balloon angioplasty or additional stenting with drug-eluting stents (DES) ( 4 – 6 ). Considering the prevalence of CTOs and their high risk of restenosis and ST following PCI, investigating the safety and efficacy of DCB treatment in CTO PCI is necessary ( 7 , 8 ).…”

Section: Introductionmentioning

confidence: 99%

Clinical Outcomes of Drug-Coated Balloon Treatment After Successful Revascularization of de novo Chronic Total Occlusions

Jun

Shin

Teoh

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundThe safety and efficacy of drug-coated balloon (DCB) treatment for de novo coronary chronic total occlusion (CTO) remain uncertain. The aim of this study was to evaluate the outcomes of DCB only treatment for de novo CTO.MethodsIn this retrospective study, 101 vessels with de novo CTO lesions dilated by balloon angioplasty with thrombolysis in myocardial infarction flow grade 3 were included. Among them, 93 vessels successfully treated with DCB only treatment were analyzed. The study endpoint was major adverse cardiac events (MACE) at 2 years, a composite of cardiac death, non-fatal myocardial infarction (MI), target vessel revascularization (TVR), and target vessel thrombosis. The secondary endpoint was late lumen loss (LLL) on follow-up coronary angiography.ResultsAll 84 patients were followed up clinically, and 67 vessels underwent scheduled coronary angiography after 6 months. There were no procedural complications, and three vessels required bailout-stenting. The median follow-up was 720 days (interquartile range [IQR]; 406–1,268 days). MACE occurred in 8.3% of the patients after 1 year, including cardiac death (1.2%), TVR (7.1%), and no non-fatal MI and target vessel thrombosis. Two years after treatment, MACE occurred in 16.7% of the patients, including cardiac death (2.4%), non-fatal MI (3.6%), TVR (13.1%), and no target vessel thrombosis. The mean LLL was 0.03 ± 0.53 mm. Binary restenosis occurred in 14.9% of the treated vessels, and 3.0% of the vessels had late re-occlusion on follow-up coronary angiography.ConclusionsIf the result of revascularization using balloon angioplasty is good, the clinical outcomes of DCB only treatment of de novo CTOs at the 2-year follow-up are encouraging, with a low rate of hard endpoints and acceptable MACE rates (Clinical Trial Registration Information; Impact of Drug-coated Balloon Treatment in de novo Coronary Lesion; NCT04619277).

show abstract

“…A Korean study using DCB alone to treat CTO demonstrated that the LLL in the DCB group was 0.03 mm, better than the DES group (0.15-0.20 mm) (108). Meanwhile, several case reports listed in Table 5 concluded that DCB is a feasible method for treating CTO lesions (110,111).…”

Section: Application Of Dcb In Chronic Total Occlusionmentioning

confidence: 99%

Novel application of drug-coated balloons in coronary heart disease: A narrative review

Wang

Li²,

Li³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The incidence of coronary heart disease (CAD) has soared over the years, and coronary intervention has become an increasingly important therapeutic approach. The past decade has witnessed unprecedented developments in therapeutic medical instruments. Given that drug-coated balloons bring many benefits, they are indicated for an increasing number of conditions. In this article, we review the results of current clinical trials about drug-coated balloons and summarize their safety and clinical progression in different coronary artery diseases, laying the groundwork for basic research, and clinical therapeutics of this patient population.

show abstract

Drug-coated balloon angioplasty: An intriguing alternative for the treatment of coronary chronic total occlusions

Cited by 11 publications

References 4 publications

Adverse Events in Primary Percutaneous Coronary Angioplasty With Drug-Eluting Stents Compared With Drug-Coated Balloons: A Retrospective Outlook

Adverse Events in Primary Percutaneous Coronary Angioplasty With Drug-Eluting Stents Compared With Drug-Coated Balloons: A Retrospective Outlook

Clinical Outcomes of Drug-Coated Balloon Treatment After Successful Revascularization of de novo Chronic Total Occlusions

Novel application of drug-coated balloons in coronary heart disease: A narrative review

Contact Info

Product

Resources

About